ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Leading with science to bring autoimmune diseases into focus

(BPT) - Sponsored by argenx

Jamilah's symptoms started when she noticed it was getting harder for her to stand up, followed by numbness and tingling sensations in her hands. Within a few months, her symptoms had progressed, and she was living in a wheelchair. Jamilah later discovered she had chronic inflammatory demyelinating polyneuropathy (CIDP).

Eri was no stranger to physical challenges. But when he kept falling while playing basketball, he and his doctors couldn't figure out why. He was having trouble swallowing and lost 20 pounds before he finally - after more than 50 tests - was diagnosed with generalized myasthenia gravis (gMG).

Jamilah and Eri are just two of the many people around the world living with an autoimmune disease. Their experiences of lengthy times to diagnosis, while battling chronic and debilitating symptoms, are shared by the millions of people living with conditions in which their own bodies are turning against them.

According to the Autoimmune Association, the average autoimmune patient sees four doctors over a period of four years before receiving a proper diagnosis. This journey to diagnosis for many patients underscores the need for education and information sharing among healthcare providers about autoimmunity and the growing availability of advanced and precision treatments.

Receiving an autoimmune disease diagnosis can bring relief but it also raises new questions about what comes next on the path to reclaiming a life that looks like it did before navigating a debilitating condition.

"Too many people face years of misdiagnosis, uncertainty, and barriers to treatment, all while managing debilitating symptoms," said Laura Simpson, Chief Operating Officer of the Autoimmune Association. "By raising awareness and prioritizing earlier diagnosis, we can change the trajectory for millions and ensure that no one navigating autoimmunity feels alone in their journey."

The impetus to address these diagnostic and therapeutic gaps is only set to intensify as the incidence rate of autoimmune conditions is forecast to rise in coming years.

A growing and underrecognized health crisis

Despite 1 in 10 people being affected by autoimmune conditions, fewer than 6% of Americans can name an autoimmune disease, the Autoimmune Association has found, leaving many patients feeling isolated and unseen.

Autoimmune diseases are often viewed in isolation and not for their cumulative impact. As a result, the healthcare ecosystem is taking a patchwork approach to addressing the burdens of each disease, rather than considering the totality of their impact.

"We need to see autoimmune disease as a crisis requiring not just medical treatment, but also visibility and compassion for people living with an autoimmune condition," said Christine Gustafson, Executive Director and CEO of the TED Community Organization. "The need has never been clearer for a concerted and sustained effort to make visible patients who remain unseen in plain sight."

This March, members of the autoimmune disease community are using Autoimmune Disease Awareness Month to highlight the need for increased investment into the research and development of innovative diagnostics and treatments, as well as improved care pathways for the millions of people facing these conditions.

"Greater investments in science and medical education to help patients get a diagnosis earlier, and precision treatment to help avoid hospitalization, are some of the ways to help reduce long-term disease and treatment burdens," said Simpson from the Autoimmune Association.

argenx is one company that is inspired by and working alongside the autoimmune disease community to help address their unmet needs. By partnering with pioneering researchers and building relationships with patients and their communities, the company is working to advance immunology breakthroughs with a goal of reaching 50,000 patients globally with their innovative treatments by 2030.

"Relentless innovation in immunology helps to ensure that people with autoimmune diseases have access to even better treatments, as quickly as possible," said Dr. Luc Truyen, Chief Medical Officer at argenx. "Getting patients the care they need and deserve requires innovation across the healthcare ecosystem. At argenx, we co-create alongside patients, because innovation has no meaning without aiming to benefit them."

Creating lasting change

Raising awareness about autoimmune diseases and the experiences of those living with them is more than just a month-long effort - it is an ongoing commitment to advance understanding, advocacy, and action.

To learn more about autoimmune diseases, the experiences of patients like Jamilah and Eri, and argenx's commitment to the autoimmune community, visit https://argenx.com/. To see more of the incredible work being done in the autoimmune community, check out https://tedcommunity.org & https://autoimmune.org/.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.